drugset
drugset / Trial / NCT05166876

Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19

NCT05166876 ↗

Phase 2 Terminated 26 enrolled Clear Creek Bio, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A Phase 2 multi-center, assessor-blind, randomized study to assess the safety, tolerability, and antiviral activity of brequinar in combination with dipyridamole.

Timeline

Start
2022-02-01
Primary completion
2022-06-04
Completion
2022-06-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Brequinar Small molecule 50 mg Oral
Subject Brequinar Small molecule 100 mg Oral
Subject Brequinar Small molecule 150 mg Oral
Subject Brequinar Small molecule 200 mg Oral
Subject Dipyridamole Other / unclassified 75 mg Oral

Indications

COVID-19